Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Expert Opin Drug Saf ; 15(10): 1329-47, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27347638

RESUMEN

INTRODUCTION: The atypical antipsychotic (APs) drugs have become the most widely used agents to treat a variety of psychoses because of their superiority with regard to safety and tolerability profile compared to conventional/'typical' APs. AREAS COVERED: We aimed at providing a synthesis of most current evidence about the safety and tolerability profile of the most clinically used atypical APs so far marketed. Qualitative synthesis followed an electronic search made inquiring of the following databases: MEDLINE, Embase, PsycINFO and the Cochrane Library from inception until January 2016, combining free terms and MESH headings for the topics of psychiatric disorders and all atypical APs as following: ((safety OR adverse events OR side effects) AND (aripiprazole OR asenapine OR quetiapine OR olanzapine OR risperidone OR paliperidone OR ziprasidone OR lurasidone OR clozapine OR amisulpride OR iloperidone)). EXPERT OPINION: A critical issue in the treatment with atypical APs is represented by their metabolic side effect profile (e.g. weight gain, lipid and glycaemic imbalance, risk of diabetes mellitus and diabetic ketoacidosis) which may limit their use in particular clinical samples. Electrolyte imbalance, ECG abnormalities and cardiovascular adverse effects may recommend a careful baseline and periodic assessments.


Asunto(s)
Antipsicóticos/efectos adversos , Enfermedades Cardiovasculares/inducido químicamente , Enfermedades Metabólicas/inducido químicamente , Enfermedades Cardiovasculares/fisiopatología , Electrocardiografía , Humanos , Enfermedades Metabólicas/fisiopatología , Equilibrio Hidroelectrolítico/efectos de los fármacos
2.
Clin Ter ; 164(5): 429-35, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24217831

RESUMEN

Daily rhythms regulate everiday life and sleep/wake alternation is the best expression of this. Disruptions in biological rhythms is strongly associated with mood disorders, often being the major feature of this, major depressive disorder first of all. Although stabilization of rhythms produced by treatments have important outcome on therapeutic efficacy, insomnia often remains an unresolved symptom when major depression has otherwise been successfully treated with antidepressant. We review scientific literature in order to better clarify how to better approach insomnia as a clinical aspect to investigate and to early treat while treating other psychiatric conditions, major depression in particular. Insomnia is associated with impaired quality of life. It can be resolved with adequate diagnosis and treatment: it should be considered a comorbid condition and should be early identificated and treated in a multidisciplinary way, so that the ideal of treatment for patients with treatment resistant insomnia in major depression is an integration of non-pharmacologic measures, along with judicious use of medication, often used as an adjunctive therapy.


Asunto(s)
Trastorno Depresivo Mayor/tratamiento farmacológico , Hipnóticos y Sedantes/uso terapéutico , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Anticonvulsivantes/farmacología , Anticonvulsivantes/uso terapéutico , Tronco Encefálico/efectos de los fármacos , Tronco Encefálico/fisiopatología , Ritmo Circadiano/efectos de los fármacos , Ritmo Circadiano/fisiología , Terapias Complementarias , Trastorno Depresivo Mayor/complicaciones , Resistencia a Medicamentos , Tolerancia a Medicamentos , Humanos , Hipnóticos y Sedantes/clasificación , Hipnóticos y Sedantes/farmacología , Melatonina/agonistas , Melatonina/uso terapéutico , Neurotransmisores/fisiología , Psicotrópicos/farmacología , Psicotrópicos/uso terapéutico , Receptores de Melatonina/agonistas , Receptores de Melatonina/fisiología , Receptores de Neurotransmisores/efectos de los fármacos , Receptores de Neurotransmisores/fisiología , Trastornos del Inicio y del Mantenimiento del Sueño/etiología , Trastornos del Inicio y del Mantenimiento del Sueño/fisiopatología , Fases del Sueño/efectos de los fármacos , Fases del Sueño/fisiología
3.
Clin Ter ; 162(6): e195-202, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22262340

RESUMEN

Psychiatric disorders are frequently associated with disturbances of sleep and circadian rhythms. This review focus on the relationship between sleep disturbances and eating disorders. In the first part are discussed the presence of sleep disorders among patients suffering from anorexia nervosa and bulimia nervosa, the macrostructure and microstructure of theirs sleep, the differences between the various subtypes in ED patients, the dreams of eating disordered patients and their recurrent contents. In the second part, there are treated sleep disturbances in binge eating disorder and other eating disorders not otherwise specified, such as nocturnal (night) eating syndrome and sleep-related eating disorder. In the third part, there are presented data concerning the neurobiological and neuroendocrinological correlates between feeding, metabolism, weight restoration and the processes regulating sleep. In conclusion, possible future investigations are proposed.


Asunto(s)
Trastornos de Alimentación y de la Ingestión de Alimentos/complicaciones , Trastornos del Sueño-Vigilia/etiología , Regulación del Apetito , Peso Corporal , Trastornos de Alimentación y de la Ingestión de Alimentos/fisiopatología , Humanos , Fenómenos Fisiológicos de la Nutrición , Sueño
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA